Revitalize Cognition: Near Infrared Stimulation in Older Adults

Aging Clinical Trial

Official title:

Revitalize Cognition: A Proof of Concept Study Using Transcranial Near Infrared Stimulation in Older Adults

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02582593
• Other study ID #: IRB201400128
• Secondary ID: 6AZ15PF-IMP-1938
• Status: Recruiting
• Phase: N/A
• Start date: December 18, 2015
• Est. completion date: November 17, 2022

Study information

• Verified date: October 2022
• Source: University of Florida
• Contact: Dawn Bowers, Ph.D.
• Phone: 352-392-3450
• Email: dawnbowers[@]phhp.ufl.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Changes in mood and cognition are common in older adulthood. Some studies have suggested that transcranial application of near-infrared (NIR) light may have enhancing effects on cognitive and mood status in young adults and individuals with traumatic brain injury. This effect has not been examined in older adults. This study will involve a randomized sham-controlled trial to learn whether NIR stimulation improves cognition and mood in older adults, relative to sham treated controls.

Description:

There is a dearth of clinically meaningful treatment options at this point in time for individuals who are at increased risk for transitioning to dementia, particularly those with the amnestic variant of mild cognitive impairment (aMCI). While waiting for causative cures and preventive approaches, investigators are faced with the task of identifying modifying therapies that might alter the course or slow down the transition from normal cognition to MCI to dementia.

The proposed study hopes to contribute to this mission by testing the viability of a different type of intervention, one involving transcranial delivery of near-infrared (NIR) wavelengths (808-904nm). Near-infrared stimulation is safe, non-invasive and appears to improve mitochondrial function by promoting increased production of intracellular adenosine triphosphate (ATP) and possibly improved blood flow. Perhaps most compelling are recent findings of reduced beta-amyloid and neurofibrillary tangles in transgenic Alzheimer's mouse models after exposure to real vs sham transcranial NIR stimulation. Preliminary human involving traumatic brain injury (TBI), stroke, and young adult populations have also been promising in terms of positive effects of NIR on cognition.

The overall goal of the present study is to learn whether this unconventional NIR stimulation approach has potential for improving cognition in older adults. To do so, investigators will conduct a randomized sham controlled pilot trial. The intervention will involve six sessions, over a 2-week period in which real or sham stimulation is transcranially applied using a delivery system that has been FDA-approved as a nonsignificant risk since 2003. Researchers hope to learn whether NIR stimulation, relative to sham, has positive effects on cognition and mood in older adults.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 180
• Est. completion date: November 17, 2022
• Est. primary completion date: November 17, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 62 Years to 99 Years

Eligibility

Inclusion Criteria:

• Age 62 years or above

• Able to provide informed consent and perform cognitive and mood measures on a computer

• Willingness to be randomized to Sham or Real intervention

• Can devote 2 weeks to the intervention, and additional time for pre and post testing

• 8th grade education and ability to read on 8th grade level based on scores on the Wechsler Test of Adult Reading (WTAR) or the Wide Range Achievement Test-IV (WRAT-IV); or a reading test at 14 pt. text

• On stable doses of major medications; Since some older adults with memory complaints may be prescribed acetylcholinererase inhibitors or related medications by their primary care physicians (i.e., donepezil, rivastigmine, galantaominhe, memantime, or other potential memory-enhancing agent(s), we will not exclude them as long as they have been on stable medications for at least two months and plan to continue this medication during study participation.

• Willingness to allow a study partner (spouse, family member, friend) to answer questions about their cognitive, mood, and other behaviors

Exclusion criteria

• Sensory loss (vision, hearing) or motor deficits that would preclude participation in the experimental cognitive tasks or neuropsychological assessment

• Unstable and uncontrolled medical conditions (metabolic encephalopathy, HIV, moderate to severe kidney or liver disease)

• Previous major strokes or other known significant brain abnormalities or diseases affecting cognition (i.e., multiple sclerosis, seizure disorder, brain surgery, moderate TBI, etc.). No history of brain surgery. Exceptions are a diagnosis of Parkinson's disease for the PD subgroup.

• Evidence of potential dementia (e.g., scores < 24 on the Mini Mental State Exam (MMSE), or < 20 on the Montreal Cognitive Assessement (MoCA), or less than 5th percentile on the Dementia Rating Scale-2 (DRS-2)

• Current or past history of major psychiatric disturbance including schizophrenia, or active psychosis, bipolar disorder, current major depressive episode, current alcohol or substance abuse or history thereof within the past six months. This will be assessed using the Mental Health Screen v.3 (Carroll & McGinley), a modification of the Structured Clinical Interview for DSM-IV psychiatric disorders. We are not excluding individuals who are taking antidepressants or anti-anxiety medications, however, use of antidepressants and anxiolytics will be recorded and data will be analyzed in post-hoc analyses

• Use of antipsychotics, sedatives, or other medications with significant anticholinergic properties (due to potential influence on memory)

• Use of photo-sensitive medications such as steroids or retin-A within 15 days of the study intervention

• Diagnosis of cancer

• Previous participation in a cognitive training study within the last 3 months or current involvement in another study at VITAL or ReVITALIZE, or another study involving cognitive training or intervention at the time of participation

Related Conditions & MeSH terms

• Aging

Intervention

Device:
• MedX 1116 Rehab Console
This intervention makes use of transcranially applied near infrared light using light emitting diodes. Near infrared light will be applied to the scalp for a period of 1 hour at each session. A total of six session will be held.
• Sham MedX 1116 Rehab Console
This intervention makes use of sham transcranially applied near infrared light using light emitting diodes. Light emitting diodes (but not near-infrared light) will be applied to the scalp for a period of 1 hour at each session. A total of six session will be held.

Locations

Country	Name	City	State
United States	The Center for Movement Disorders and Neurorestoration	Gainesville	Florida
United States	The Village Retirement Community	Gainesville	Florida

Sponsors (3)

Lead Sponsor	Collaborator
University of Florida	FL DEPT OF HLTH ED ETHEL MOORE ALZHEIMER, Parkinson's Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	NIH Examiner Battery, Executive Composite changes from baseline to post-testing	Computer-based battery of executive functioning tests which yields a total or "composite" score to represent global executive functioning. Executive composite scores can range from -3.0 to 3.0, with higher scores corresponding to better executive functioning, and negative scores indicating impairment. A change score will be calculated by subtracting the baseline scores from the post-test scores.	Change in baseline to approximately week 3
Secondary	Loewenstein-Acevedo Scale of Semantic Interference and Learning (LASSI-L) Free Delayed Recall changes from baseline to post-testing	The LASSI-L is a 15 item word list learning task that instructs a participant to remember a list of common words (fruits, musical instruments, or articles of clothing with 5 words per category) after interference and delay. The delayed recall score ranges from 0-15. A change score will be calculated by subtracting the baseline scores from the post-test scores.	Change in baseline to approximately week 3
Secondary	NIH Toolbox Emotion Psychological Wellbeing Scale changes from baseline to post-testing	The Psychological Wellbeing Scale from the NIH Toolbox Emotion module Wellbeing Scale results in T-scores (mean=50, SD=10) for categories such as positive affect, life satisfaction, and meaning and purpose. Scores below 40 indicate low levels of wellbeing and scores above 60 indicating high levels of wellbeing. Change scores will be calculated by subtracting the baseline scores from the post-test scores.	Change in baseline to approximately week 3
Secondary	NIH Toolbox Emotion Negative Affect Scale changes from baseline to post-testing	The Negative Affect Scale from the NIH Toolbox Emotion module results in T-scores (mean=50, SD=10) for categories such as anger, sadness, and apathy. Scores below 40 indicate low levels of negative affect and scores above 60 indicate high levels of negative affect. Change scores will be calculated by subtracting the baseline scores from the post-test scores.	Change in baseline to approximately week 3